The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors.
Lindsay P. Cameron, Alaina M Jaster, Raul A Ramos, Elijah Z. Ullman
Molecular Pharmacology 2026 DOI: 10.1016/j.molpha.2025.100093 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Serotonin |
| Keywords | Amphetamines Psychedelic Receptor pharmacology Research methods Serotonin receptors |
| Citations | 3 |
| Key findings | DOI has been a key pharmacological tool for studying 5-HT2A and 5-HT2C receptors in over 1,200 publications, but its potential scheduling may restrict future research, prompting the need for alternative compounds. |
Abstract
2,5-dimethoxy-4-iodoamphetamine (DOI) is a phenethylamine psychedelic with high affinity for 5-HT2 receptors. In 2022 and 2023, the US Drug Enforcement Administration proposed to place DOI, along with a similar compound, 2,5-dimethoxy-4-chloroamphetamine, in Schedule I of the Controlled Substances Act based on their psychoactivity and alleged abuse potential. Here, we describe the history of DOI, its utility in preclinical neuroscience research, and how it has significantly advanced the study of 5-HT2A and 5-HT2C receptors. Finally, we suggest alternative compounds for studying 5-HT2 receptors, should obtaining DOI for research become restricted. SIGNIFICANCE STATEMENT: 2,5-Dimethoxy-4-iodoamphetamine, the key pharmacological tool for studying 5-HT2A receptor function and localization, has been used in more 1200 publications across 5 decades. This review covers its utility, research barriers if the Drug Enforcement Administration schedules it, and alternatives for continued investigation of serotonin receptors.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 2
- Reducing Research Harms: Analysis and Recommendations for Researching Schedule I Substances Under the HALT Fentanyl Act Journal of Science Policy & Governance July 2, 2026
- Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations. Research Square April 23, 2026
Cites 79
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
and 74 more in the library